Not yet recruitingN/A

Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

NCT07588334 · LSD-LPPH · Northern Jiangsu People's Hospital

Closed to entry

Status

Not accepting participants

Not applicable

Phase

Target enrolment

Study sites

Outside the US

What it is testing

Summary

Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Total cholesterol (TC) level
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24
Total triglycerides (TG) level
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24
High-density lipoprotein cholesterol (HDL-C)
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24
Low-density lipoprotein cholesterol (LDL-C)
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 80 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion Criteria: 1. Age 18-80 years, male or female 2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging) 3. Splenomegaly and hypersplenism 4. History of portal hypertension bleeding (esophageal and gastric variceal bleeding ) 5. Child-Pugh Class A or B liver function 6. Signed written informed consent 7. Ability to complete 24-month follow-up Exclusion Criteria: 1. Child-Pugh Class C liver cirrhosis 2. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection 3. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders 4. Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery. 5. Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases. 6. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery 7. Pregnancy or lactation 8. Poor compliance, inability to complete follow-up

Where

1 study site

Facility	City	Region	Country
Clinical Medical College of Yangzhou University	Yangzhou	Jiangsu	China

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07588334 on ClinicalTrials.gov →

Last updated in the registry 2026-05-14. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Indication

All 4 trials from Northern Jiangsu People's Hospital →